Expression of SIL-2R in Patients with Multiple Myeloma and Its Clinical Significance.
10.19746/j.cnki.issn.1009-2137.2022.06.026
- Author:
Ping LIN
1
;
Xiao-Rong LIN
1
;
Qiao-Ling LIU
1
;
Xue-Ya ZHANG
2
;
Gen-Wang CHEN
1
;
Ruo-Teng XIE
1
;
Ya-Lan ZHANG
1
;
Xiu-Huan DU
1
Author Information
1. Department of Laboratory Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
2. Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China,E-mail: jakey3456@sina.com.
- Publication Type:Journal Article
- Keywords:
clinical significance;
multiple myeloma;
prognosis;
sIL-2R
- MeSH:
Humans;
Calcium;
Clinical Relevance;
Creatinine;
Lactate Dehydrogenases;
Multiple Myeloma;
Receptors, Interleukin-2
- From:
Journal of Experimental Hematology
2022;30(6):1797-1802
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significance of soluble interleukin-2 receptor(sIL-2R) in patients with multiple myeloma(MM).
METHODS:54 newly diagnosed MM patients in the Second Affiliated Hospital of Fujian Medical University from February 2020 to December 2021 were selected as the observation group, and 60 healthy people in our hospital in the same period were selected as the control group. The expression levels of sIL-2R in the serum of the two groups were detected by enzyme-linked immunosorbent assay. The differences of sIL-2R expression level among different clinical parameter groups in MM patients were compared. The clinical parameters include:gender, age, ISS stage, hemoglobin, albumin, serum creatinine, lactate dehydrogenase and β2-microglobulin, blood calcium, bone marrow plasma cell ratio and treatment response. The relationship between sIL-2R expression level and progression-free survival(PFS) and overall survival(OS) in MM patients were analyzed.
RESULTS:The expression of serum SIL-2R in MM patients was significantly higher than that in healthy control group (P<0.05). The expression of sIL-2R in MM patients who did not achieve complete remission(CR) was significantly higher than those of CR patients (P=0.037). There was no significant difference in the expression of serum sIL-2R between the groups of different sex, age, ISS stage, hemoglobin concentration, albumin content, serum creatinine level, lactate dehydrogenase level, the content of β2-microglobulin, the concentration of blood calcium, and the proportion of bone marrow plasma cells(P>0.05). The PFS of sIL-2R high expression group(15 months) was shorter than that of sIL-2R low expression group (22 months), which was significant difference (P=0.041). But there was no significant difference in OS between sIL-2R high expression group and sIL-2R low expression group (P=0.124). Univariate analysis results showed that the high expression of serum sIL-2R was associated with poor PFS in MM patients. Multivariate analysis results showed that the high expression of serum sIL-2R was still an independent adverse prognostic factor for PFS in MM patients, However, the expression of serum sIL-2R was not statistically significant in evaluating OS in MM patients by univariate and multivariate analysis.
CONCLUSION:The expression of serum sIL-2R in MM patients was significantly higher than that in healthy people. Serum sIL-2R is an independent prognostic factor of PFS in MM patients.
